Literature DB >> 24897506

Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2.

S Manni1, D Toscani2, E Mandato1, A Brancalion1, L Quotti Tubi1, P Macaccaro1, A Cabrelle3, F Adami4, R Zambello1, C Gurrieri1, G Semenzato1, N Giuliani2, F Piazza1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24897506     DOI： 10.1038/leu.2014.178

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4.

Authors:  Gregory Helbig; Kent W Christopherson; Poornima Bhat-Nakshatri; Suresh Kumar; Hiromitsu Kishimoto; Kathy D Miller; Hal E Broxmeyer; Harikrishna Nakshatri
Journal:  J Biol Chem       Date:  2003-04-09       Impact factor: 5.157

2.  Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.

Authors:  L R Martins; P Lúcio; A Melão; I Antunes; B A Cardoso; R Stansfield; M T S Bertilaccio; P Ghia; D Drygin; M G Silva; J T Barata
Journal:  Leukemia       Date:  2013-08-08       Impact factor: 11.528

Review 3.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

4.  CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Authors:  Adam Siddiqui-Jain; Denis Drygin; Nicole Streiner; Peter Chua; Fabrice Pierre; Sean E O'Brien; Josh Bliesath; Mayuko Omori; Nanni Huser; Caroline Ho; Chris Proffitt; Michael K Schwaebe; David M Ryckman; William G Rice; Kenna Anderes
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

5.  HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB.

Authors:  Paola Maroni; Paola Bendinelli; Emanuela Matteucci; Maria Alfonsina Desiderio
Journal:  Carcinogenesis       Date:  2006-07-13       Impact factor: 4.944

6.  A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.

Authors:  Ying Zheng; Hongwei Qin; Stuart J Frank; Luqin Deng; David W Litchfield; Ayalew Tefferi; Animesh Pardanani; Fang-Tsyr Lin; Jingzhi Li; Bingdong Sha; Etty N Benveniste
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

Review 7.  Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Authors:  K Podar; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2008-10-09       Impact factor: 11.528

Review 8.  New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

Authors:  Nicola Giuliani; Simona Colla; Vittorio Rizzoli
Journal:  Exp Hematol       Date:  2004-08       Impact factor: 3.084

9.  Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.

Authors:  Kenneth H Shain; Danielle N Yarde; Mark B Meads; Mei Huang; Richard Jove; Lori A Hazlehurst; William S Dalton
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

10.  Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

Authors:  Sabrina Manni; Alessandra Brancalion; Elisa Mandato; Laura Quotti Tubi; Anna Colpo; Marco Pizzi; Rocco Cappellesso; Fortunato Zaffino; Speranza Antonia Di Maggio; Anna Cabrelle; Filippo Marino; Renato Zambello; Livio Trentin; Fausto Adami; Carmela Gurrieri; Gianpietro Semenzato; Francesco Piazza
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240
View more
  10 in total

1.  MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages.

Authors:  Jihane Khalife; Jayeeta Ghose; Marianna Martella; Domenico Viola; Alberto Rocci; Estelle Troadec; Cesar Terrazas; Abhay R Satoskar; Emine Gulsen Gunes; Ada Dona; James F Sanchez; P Leif Bergsagel; Marta Chesi; Alex Pozhitkov; Steven Rosen; Guido Marcucci; Jonathan J Keats; Craig C Hofmeister; Amrita Krishnan; Enrico Caserta; Flavia Pichiorri
Journal:  JCI Insight       Date:  2019-11-01

Review 2.  Targeting CK2-driven non-oncogene addiction in B-cell tumors.

Authors:  E Mandato; S Manni; F Zaffino; G Semenzato; F Piazza
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

3.  Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.

Authors:  Sabrina Manni; Marilena Carrino; Martina Manzoni; Ketty Gianesin; Sara Canovas Nunes; Matteo Costacurta; Laura Quotti Tubi; Paolo Macaccaro; Elisa Taiana; Anna Cabrelle; Gregorio Barilà; Annalisa Martines; Renato Zambello; Laura Bonaldi; Livio Trentin; Antonino Neri; Gianpietro Semenzato; Francesco Piazza
Journal:  Oncotarget       Date:  2017-02-28

Review 4.  Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.

Authors:  Sabrina Manni; Marilena Carrino; Gianpietro Semenzato; Francesco Piazza
Journal:  Int J Mol Sci       Date:  2018-05-18       Impact factor: 5.923

Review 5.  Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2.

Authors:  Zaira Spinello; Anna Fregnani; Laura Quotti Tubi; Livio Trentin; Francesco Piazza; Sabrina Manni
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

6.  Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.

Authors:  Sabrina Manni; Maria Pesavento; Zaira Spinello; Lara Saggin; Arash Arjomand; Anna Fregnani; Laura Quotti Tubi; Greta Scapinello; Carmela Gurrieri; Gianpietro Semenzato; Livio Trentin; Francesco Piazza
Journal:  Front Cell Dev Biol       Date:  2022-08-11

7.  CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma.

Authors:  Anna Fregnani; Lara Saggin; Ketty Gianesin; Laura Quotti Tubi; Marco Carraro; Gregorio Barilà; Greta Scapinello; Giorgia Bonetto; Maria Pesavento; Tamara Berno; Antonio Branca; Carmela Gurrieri; Renato Zambello; Gianpietro Semenzato; Livio Trentin; Sabrina Manni; Francesco Piazza
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

Review 8.  Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells.

Authors:  Carolyne Falank; Heather Fairfield; Michaela R Reagan
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-17       Impact factor: 5.555

Review 9.  Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.

Authors:  Sabrina Manni; Marilena Carrino; Francesco Piazza
Journal:  J Hematol Oncol       Date:  2017-10-02       Impact factor: 17.388

10.  Synthetic Peptide CK2.3 Enhances Bone Mineral Density in Senile Mice.

Authors:  John Nguyen; Hilary Weidner; Lora M Schell; Linda Sequeira; Ryan Kabrick; Saurabh Dharmadhikari; Harold Coombs; Randall L Duncan; Liyun Wang; Anja Nohe
Journal:  J Bone Res       Date:  2018-06-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.